Aaron S. Meadows

Feasibility and Safety of Systemic rAAV9-h <i>NAGLU</i> Delivery for Treating Mucopolysaccharidosis IIIB: Toxicology, Biodistribution, and Immunological Assessments in Primates

Darren Murrey, Bartholomew J. Naughton, F. Jason Duncan et al. · Human Gene Therapy Clinical Development · 2014 · 88 citations · Full text

Medicine, Pharmacology, Toxicology +15

Blood Genome-Wide Transcriptional Profiles Reflect Broad Molecular Impairments and Strong Blood-Brain Links in Alzheimer's Disease

Bartholomew J. Naughton, F. Jason Duncan, Darren Murrey et al. · Journal of Alzheimer s Disease · 2014 · 61 citations

Life Sciences, Genetics, Neuroscience +17

Functional correction of neurological and somatic disorders at later stages of disease in MPS IIIA mice by systemic scAAV9-hSGSH gene delivery

Haiyan Fu, Marcela P. Cataldi, Tierra Ware et al. · Molecular Therapy — Methods & Clinical Development · 2016 · 61 citations · Full text

Medicine, Neurology, Neuroscience +17

Differential Prevalence of Antibodies Against Adeno-Associated Virus in Healthy Children and Patients with Mucopolysaccharidosis III: Perspective for AAV-Mediated Gene Therapy

Haiyan Fu, Aaron S. Meadows, Ricardo Pineda et al. · Human Gene Therapy Clinical Development · 2017 · 43 citations · Full text

Medicine, Molecular Medicine, Pediatrics +11

Effective Depletion of Pre-existing Anti-AAV Antibodies Requires Broad Immune Targeting

Victoria M. Velazquez, Aaron S. Meadows, Ricardo Pineda et al. · Molecular Therapy — Methods & Clinical Development · 2017 · 39 citations · Full text

Life Sciences, Immunology, Pharmacology +17